Maria Giulia Mosconi (Italy)
Università degli studi di Perugia - Azienda Ospedaliera di Perugia
Cardiovascular and emergency medicine - Stroke Unit
I graduated in 2012 at Medicine Faculty of Perugia University then I specialized in Emergency Medicine in Perugia University on 2018. Since 2015 I had national and international collaborations regarding cardio-vascular and especially stroke medicine. On September 2021, I work for the Uniersity of Perugia in association with Perugia S.Maria della Miserricordia Hospital as Clinical resercher in Internal Medicin, my reserch project is on ischemic stroke recurrence. My research intersts are: acute treatment of ischemic stroke stroke, cardio-embolic stroke and its secondary prevention, intracerebral hemorrahge.

Presenter of 1 Presentation

 Conference Calendar

SYSTEMIC THROMBOLYSIS IN PATIENTS WITH ACUTE STROKE AND ACTIVE CANCER: A SYSTEMATIC REVIEW AND META-ANALYSIS

Session Name
0870 - Acute Stroke Therapy 2 (ID 77)
Session Type
Free Communication Session
Date
29.10.2021, Friday
Session Time
15:15 - 16:45
Room
FREE COMMUNICATIONS A
Presenter
Lecture Time
16:05 - 16:15

Abstract

Background and Aims

Cancer patients frequently have concomitant cerebrovascular diseases, which significantly worsen their prognosis. Prospective studies validating intravenous thrombolysis (IVT) safety profile in patients with acute ischemic stroke and active cancer are still lacking. Our aim was to evaluate efficacy and safety profile of IVT in acute ischemic stroke patients with comorbid active cancer.

Methods

We included in a meta-analysis all relevant published studies including patients with acute ischaemic stroke with or without active cancer, and receiving IVT, according to recommendations for IVT treatment for acute ischaemic stroke. The primary outcomes were all-cause mortality, any intracerebral haemorrhage and functional outcome, reported as modified Rankin Scale (mRS).

Results

ich.pngNine studies were included in the meta-analysis. IVT was not associated with a significant increase in the incidence of intracerebral haemorrhage (OR 1.00; 95%CI 0.76 – 1.33; I2 48.07%), nor with a significant increase in death for any cause (OR 1.13; 95%CI 0.90 – 1.43; I2 51.6%); furthermore, IVT did not influence mRS between cancer and non-cancemortality.pngmrs.pngr stroke patients (OR 1.00; 95%CI 0.58 – 1.71; I2 27.42%).

Conclusions

IVT seems to be safe and effective on patients affected by an ischemic stroke and concomitant cancer. Due to the low overall quality of the evidence, high-quality randomized control trials with adequate sample sizes are needed.

Hide